These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18428082)

  • 21. Perspectives. Orphan Drug Act stumps lawmakers.
    Firshein J
    Faulkner Grays Med Health; 1990 Jun; 44(25):suppl 4 p.. PubMed ID: 10105023
    [No Abstract]   [Full Text] [Related]  

  • 22. New developments in antiinfectives research for tropical infectious diseases.
    Chibale K
    Bioorg Med Chem; 2015 Aug; 23(16):5085-6. PubMed ID: 26014483
    [No Abstract]   [Full Text] [Related]  

  • 23. The Health Impact Fund: a potential solution to inequity in global drug access.
    Banerjee A; Pogge T
    Indian J Med Ethics; 2010; 7(4):240-3. PubMed ID: 22106579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Introduction-Current activities and future goals of orphan disease agencies.
    Van Woert MH
    Prog Clin Biol Res; 1985; 197():3-6. PubMed ID: 4070296
    [No Abstract]   [Full Text] [Related]  

  • 25. [Pharmaceutical development concerning diseases predominating in tropical regions: the concept of indigent drugs].
    Trouiller P; Rey JL; Bouscharain P
    Ann Pharm Fr; 2000 Jan; 58(1):43-6. PubMed ID: 10669812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Control of neglected tropical diseases: integrated chemotherapy and beyond.
    Utzinger J; de Savigny D
    PLoS Med; 2006 Jan; 3(5):e112. PubMed ID: 16435910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 28. Saving orphan drug legislations: misconceptions and clarifications.
    Hyry HI; Cox TM; Roos JC
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(1):111-7. PubMed ID: 26768506
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug legislation. Drug companies divided.
    Gershon D
    Nature; 1990 May; 345(6270):6. PubMed ID: 2330052
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmaceuticals. Adopt an orphan.
    Karr A
    Health Serv J; 1999 Nov; 109(5681):28. PubMed ID: 10724720
    [No Abstract]   [Full Text] [Related]  

  • 31. What is wrong with orphan drug policies? Suggestions for ways forward.
    Kanavos P; Nicod E
    Value Health; 2012 Dec; 15(8):1182-4. PubMed ID: 23244822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pricing for orphan drugs: will the market bear what society cannot?
    O'Sullivan BP; Orenstein DM; Milla CE
    JAMA; 2013 Oct; 310(13):1343-4. PubMed ID: 24084916
    [No Abstract]   [Full Text] [Related]  

  • 33. Broken drug markets in infectious diseases: Opportunities outside the private sector?
    Alpern JD; Dunlop SJ; Stauffer WM
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007190. PubMed ID: 30973876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoption agent.
    Peota C
    Minn Med; 2005 Mar; 88(3):8-9. PubMed ID: 15852583
    [No Abstract]   [Full Text] [Related]  

  • 35. Singapore infectious diseases comes of age.
    Allen DM
    Singapore Med J; 1994 Jun; 35(3):314-5. PubMed ID: 7997913
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharma Dynamics: targeting safe, effective and affordable medication for South Africa and neighbouring countries.
    Cardiovasc J Afr; 2009; 20(1):85. PubMed ID: 19287824
    [No Abstract]   [Full Text] [Related]  

  • 37. Neglected diseases: getting less neglected?
    Senior K
    Drug Discov Today; 2005 Jul; 10(13):878. PubMed ID: 15993802
    [No Abstract]   [Full Text] [Related]  

  • 38. Regulation. Bill due for drugmakers' winning strategy.
    Lee J
    Mod Healthc; 2014 Jun; 44(22):10. PubMed ID: 24946373
    [No Abstract]   [Full Text] [Related]  

  • 39. Plans struggle for control of specialty pharma costs.
    Carroll J
    Manag Care; 2005 Sep; 14(9):41-2, 45-8. PubMed ID: 16238258
    [No Abstract]   [Full Text] [Related]  

  • 40. Merck Serono targets convenient, affordable medicines for patients at risk.
    Cardiovasc J Afr; 2009; 20(1):77. PubMed ID: 19287822
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.